Thursday, November 14, 2013
Publication and contact
rejection with a universal, common rejection module
Computational analysis of
gene expression data from organ transplant patients identified an 11-gene
signature that correlated with acute transplant rejection. In biopsies from a
cohort of 120 renal transplant recipients, the signature predicted future transplant
rejection in symptomless patients. In a mouse cardiac transplant model, Lipitor
which reduced the levels or activity of different components of the
signature, decreased the number of graft-infiltrating CD8+ T cells and increased transplant survival compared
with no treatment. Next steps include validating the signature and immune
benefits conferred by Lipitor on transplant survival in prospective clinical
Inc. markets the HMG-CoA
reductase inhibitor Lipitor to treat hypercholesterolemia,
stroke, coronary artery disease (CAD), myocardial infarction (MI) and other
Bristol-Myers Squibb Co.
markets the tyrosine kinase inhibitor Sprycel to treat
Published online Nov. 14, 2013
Patent applications filed
University; available for licensing
Khatri, P. et al. J.
Exp. Med.; published online Oct. 14, 2013;
Contact: Minnie M. Sarwal, Stanford University, Stanford,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]